NEW YORK (GenomeWeb News) — Rosetta Genomics today said that a Columbia University Medical Center lab will validate the company’s microRNA-based diagnostics program for Cancer of Unknown Primary.
 
The agreement calls for the company to provide the school’s Clinical Laboratory Improvement Amendments-certified lab with its protocol for diagnosing the primary origin of metastatic cancers, which will then be tested and validated using blinded samples provided by the medical center.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

The Economist writes that an increasing number of scientific journals don't do peer review.

In Science this week: genetic overlap among many psychiatric disorders, and more.

Jul
19
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.